Literature DB >> 971715

Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses.

P Collste, M Garle, M D Rawlins, F Sjöqvist.   

Abstract

A gas chromatographic method has been employed to determine chlorthalidone in plasma and whole blood after therapeutic doses. Radioactively labelled chlorthalidone was used for in vitro studies of the uptake of chlorthalidone from plasma by red blood cells. Chlorthalidone was markedly concentrated in red cells and as a compartment they would account for at least 30% of total drug in the body after multiple doses. The ratio between the plasma and red cell concentration of chlorathidone varied between individuals. After a single oral dose of 50 mg in 6 healthy volunteers chlorthalidone was eliminated with a half-life of 51 to 89 hours. The apparent volume of distribution varied between 3 and 13 1/kg and the clearance between 53 and 145 ml/min. The mean steady-state plasma concentrations during treatment with a standard dose of 50 mg daily (n = 10) varied 5-fold between individuals. During the steady state approximately 50% of the daily dose was excreted unchanged in the urine during 24 hrs. The plasma levels observed in patients were higher than those preducted from the single oral dose studies in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971715     DOI: 10.1007/BF00561667

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Application of the extractive alkylation technique to the gas chromatographic determination of chlorthalidone in plasma in nanogram quantities.

Authors:  M Ervik; K Gustavii
Journal:  Anal Chem       Date:  1974-01       Impact factor: 6.986

2.  Improved method for estimating chlorthalidone in body fluids.

Authors:  M G Tweeddale; R I Ogilvie
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

Review 3.  Carbonic anhydrase: chemistry, physiology, and inhibition.

Authors:  T H Maren
Journal:  Physiol Rev       Date:  1967-10       Impact factor: 37.312

4.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

5.  Interindividual differences in drug oxidation: clinical importance.

Authors:  F Sjöqvist; C von Bahr
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

6.  Binding-site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells.

Authors:  B Beermann; K Hellström; B Lindström; A Rosén
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

  6 in total
  11 in total

1.  Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man.

Authors:  H L Fleuren; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1977-08

Review 2.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.

Authors:  E Riva; P L Farina; R Sega; G Tognoni; W Bastain; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

4.  Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects.

Authors:  O Brørs; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

Review 5.  Chlorthalidone: mechanisms of action and effect on cardiovascular events.

Authors:  George C Roush; Venkata Buddharaju; Michael E Ernst; Theodore R Holford
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 6.  Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.

Authors:  Eric K Judd; David A Calhoun; David G Warnock
Journal:  Semin Nephrol       Date:  2014       Impact factor: 5.299

7.  Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.

Authors:  Carolina Ameijeiras Rodríguez; Sara Carolina Henriques; Aymara Sancho-Araiz; Iñaki F Trocóniz; Luis Almeida; Nuno Elvas Silva
Journal:  Pharm Res       Date:  2021-12-21       Impact factor: 4.200

8.  Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.

Authors:  H L Fleuren; T A Thien; C P Verwey-van Wissen; J M van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

9.  The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.

Authors:  Selma Sahin; Leslie Z Benet
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

10.  Azilsartan/chlorthalidone combination therapy for blood pressure control.

Authors:  Judy Wm Cheng
Journal:  Integr Blood Press Control       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.